Kuur Therapeutics

About:

Kuur Therapeutics is committed to transforming the lives of patients with cancer & is leading the development cell therapies.

Website: https://kuurtx.com/

Twitter/X: CellMedica

Top Investors: Invesco, Wellcome Trust, Salica, Imperial Innovations, Woodford Investment Management

Description:

Kuur Therapeutics is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology of a specific subset of cytotoxic T cells, called natural killer T cells (NKT cells) and innovative CAR construct engineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors.

Total Funding Amount:

$192M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2005-01-01

Contact Email:

info(AT)kuurtx.com

Founders:

Gregg Sando

Number of Employees:

51-100

Last Funding Date:

2021-01-18

IPO Status:

Private

Industries:

© 2025 bioDAO.ai